Cyclacel Pharmaceuticals, Inc. (CYCC)
- Previous Close
2.1800 - Open
2.1800 - Bid 1.6200 x 200
- Ask 2.3000 x 100
- Day's Range
2.1800 - 2.3250 - 52 Week Range
1.3000 - 13.2000 - Volume
24,780 - Avg. Volume
816,012 - Market Cap (intraday)
3.351M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-26.7500 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
www.cyclacel.comRecent News: CYCC
Performance Overview: CYCC
Trailing total returns as of 5/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCC
Valuation Measures
Market Cap
3.19M
Enterprise Value
412.90k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.69
Price/Book (mrq)
--
Enterprise Value/Revenue
0.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.33%
Return on Equity (ttm)
-272.63%
Revenue (ttm)
420k
Net Income Avi to Common (ttm)
-22.76M
Diluted EPS (ttm)
-26.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.38M
Total Debt/Equity (mrq)
6.10%
Levered Free Cash Flow (ttm)
-11.76M
Research Analysis: CYCC
Company Insights: CYCC
CYCC does not have Company Insights